Connect with us
Lykos Therapeutics hit a major roadblock Friday in its bid to bring the first psychedelic-based therapy for post-traumatic stress disorder to market, as U.S. regulators rejected...
The company plans to use the funds for research and development on its psychedelic treatments for anxiety. New York-based Mind Medicine (Nasdaq: MNMD) announced a new...
After markets closed on Wednesday, Relmada Therapeutics, Inc. (Nasdaq: RLMD) delivered its financial results for the second quarter ending June 30, 2024. The company does not...
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) reported unaudited financial results for its first quarter ended June 30, 2024, with no revenue to report at...
A new survey suggests investors are interested in psychedelic stocks, but that isn’t translating into growing investment just yet. The study, conducted by Quantum Research Group...
Healing Realty Trust announced Tuesday new partnerships with three mental health providers, expanding its clinic-focused portfolio across Florida, Massachusetts and Arizona. The real estate investment company...
Clearmind hopes to capitalize on the addiction treatment properties of MEAI. Clearmind Medicine Inc. (Nasdaq: CMND) announced that a new article published on ACS Pharmacology &...
The trial is studying the effects of psilocybin on patients with generalized anxiety disorder. Incannex Healthcare Inc. (Nasdaq: IXHL) has received approval from the US Food...
Compass Pathways (NASDAQ: CMPS) reported a wider loss for the second quarter ending June 30, while its late-stage clinical trials for depression treatment edge closer to...
PATOO naturally harvests Jamaican psilocybin mushrooms for its products. Jamaican pharmacy chain Fontana Pharmacy has partnered with the country’s first legal psychedelic consumer packaged good company...
